Selective serotonin reuptake inhibitors (SSRIs), which treat major depressive disorder by inhibiting SERT, display SERT occupancy of 80% at minimally efficacious doses [27] with 85% SERT occupancy at higher doses often used clinically [28]. This evidence concerns the gene SLC6A4 and major depressive disorder.